Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FES-PET and FDG-PET to identify benefit from palbociclib plus letrozole in ER-positive metastatic breast cancer
NL-OMON46198Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib and letrozole in breast cancer, sponsored by University Medical Center Groningen. Primary endpoint: Relation of low baseline FES-PET uptake to lesion-level non-response. Started Sep 2016; status: active, not recruiting.
02
Drugs
palbociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON46198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46198.